Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcus Biosciences Inc RCUS

Healthcare Biotechnology
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical... see more

Recent & Breaking News (NYSE:RCUS)

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study

Business Wire December 19, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire December 9, 2022

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

Business Wire November 28, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire November 24, 2022

Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Business Wire November 14, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire November 9, 2022

Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update

Business Wire November 2, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire October 25, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire October 11, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire September 26, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire September 9, 2022

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Business Wire August 24, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire August 24, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire August 9, 2022

Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer

Business Wire August 8, 2022

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

Business Wire August 3, 2022

Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Business Wire July 27, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire July 26, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire July 11, 2022

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire June 24, 2022